Baxter International, Inc. Announces Collaboration with Chatham Therapeutics for Factor IX Hemophilia B Gene Therapy Treatment

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of potential treatments for hemophilia B utilizing Chatham’s gene therapy technology.

Back to news